Drug-coated balloons to treat fem-pop disease

April 27, 2014– Interviewed by Steven E. Greer, MD

At the Charing Cross symposium in London, Medtronic reported results of the IN-PACT trial of their paclitaxel balloon. 12-month patency rates were 82%, compared to angioplasty-alone rates of 52%.

We interviewed UCLA vascular surgeon Brian DeRubertis, M.D. to put the data in perspective. Bard also has a balloon-coated product.

This entry was posted in - Medical Devices, Cardiac surgery, Cardiology, UCLA. Bookmark the permalink.

Leave a Reply